[1]
Adaniel, C.; Kirchhoff, T. Introduction to epidemiology of breast and ovarian cancers. Ann. Oncol., 2013, 24(Suppl. 8), 61-62.
[2]
Li, K.; Hüsing, A.; Fortner, R.T.; Tjønneland, A.; Hansen, L.; Dossus, L.; Chang-Claude, J.; Bergmann, M.; Steffen, A.; Bamia, C.; Trichopoulos, D.; Trichopoulou, A.; Palli, D.; Mattiello, A.; Agnoli, C.; Tumino, R.; Onland-Moret, N.C.; Peeters, P.H.; Bueno-de-Mesquita, H.B.; Gram, I.T.; Weiderpass, E.; Snchez-Cantalejo, E.S.; Chirlaque, M-D.; Duell, E.J.; Ardanaz, E.; Idahl, A.; Lundin, E.; Khaw, K.; Travis, R.C.; Merritt, M.A.; Gunter, M.J.; Riboli, E.; Ferrari, P.; Terry, K.; Cramer, D.; Kaaks, R. An epidemiologic risk prediction model for ovarian cancer in Europe: The EPIC study. Br. J. Cancer, 2015, 112(7), 1257-1265.
[3]
Baldwin, L.A.; Huang, B.; Miller, R.W.; Tucker, T.; Goodrich, S.T.; Podzielinski, I.; DeSimone, C.P.; Ueland, F.R.; Nagell, J.R.; van Seamon, L.G. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol., 2012, 120(3), 612-618.
[4]
Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian cancer. Lancet, 2014, 384(9951), 1376-1388.
[5]
Agarwal, R.; Kaye, S.B. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer, 2003, 3(7), 502-516.
[6]
Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15), 1869-1883.
[7]
Herzog, T.J. The current treatment of recurrent ovarian cancer. Curr. Oncol. Rep., 2006, 8(6), 448-454.
[8]
Chester, C.; Dorigo, O.; Berek, J.S.; Kohrt, H. Immunotherapeutic approaches to ovarian cancer treatment. J. Immunother. Cancer, 2015, 3(1), 7.
[9]
Beatty, G.L.; Gladney, W.L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res., 2014, 21(4), 687-692.
[10]
Kazemi, M.H.; Mohseni, S.R.; Hojjat-Farsangi, M.; Anvari, E.; Ghalamfarsa, G.; Mohammadi, H.; Jadidi-Niaragh, F. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. J. Cell. Physiol., 2017, 233(3), 2032-2057.
[11]
Gessi, S.; Merighi, S.; Sacchetto, V.; Simioni, C.; Borea, P.A. Adenosine receptors and cancer. Biochim. Biophys. Acta BBABiomembr., 2011, 1808(5), 1400-1412.
[12]
Klink, M. Interaction of Immune and Cancer Cells; Springer Vienna, 2013.
[13]
Blay, J.; White, T.D.; Hoskin, D.W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res., 1997, 57(13), 2602-2605.
[14]
Virgilio, F.D.; Falzoni, S.; Giuliani, A.L.; Adinolfi, E. P2 receptors in cancer progression and metastatic spreading. Curr. Opin. Pharmacol., 2016, 29, 17-25.
[15]
Virgilio, F.D.; Adinolfi, E. Extracellular purines, purinergic receptors and tumor growth. Oncogene, 2016, 36(3), 293-303.
[16]
Muller-Haegele, S.; Muller, L.; Whiteside, T.L. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev. Clin. Immunol., 2014, 10(7), 897-914.
[17]
Sousa, J.B.; Fresco, P.; Diniz, C.; Goncalves, J. Adenosine receptor ligands on cancer therapy: A review of patent literature. Rec. Pat. Anticancer Drug Discov., 2018, 13(1), 40-69.
[18]
Young, A.; Ngiow, S.F.; Barkauskas, D.S.; Sult, E.; Hay, C.; Blake, S.J.; Huang, Q.; Liu, J.; Takeda, K.; Teng, M.W.L.; Sachsenmeier, K.; Smyth, M. Co-inhibition of cd73 and a2ar adenosine signaling improves anti-tumor immune responses. Cancer Cell, 2016, 30(3), 391-403.
[19]
Preti, D.; Baraldi, P.G.; Moorman, A.R.; Borea, P.A.; Varani, K. History and perspectives of a2aadenosine receptor antagonists as potential therapeutic agents. Med. Res. Rev., 2015, 35(4), 790-848.
[20]
Gessi, S.; Bencivenni, S.; Battistello, E.; Vincenzi, F.; Colotta, V.; Catarzi, D.; Varano, F.; Merighi, S.; Borea, P.A.; Varani, K. Inhibition of a2a adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455. Front. Pharmacol., 2017, 8, 888.
[21]
Mediavilla-Varela, M.; Luddy, K.; Noyes, D.; Khalil, F.K.; Neuger, A.M.; Soliman, H.; Antonia, S.J. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol. Ther., 2013, 14(9), 860-868.
[22]
Chen, J.F.; Eltzschig, H.K.; Fredholm, B.B. Adenosine receptors as drug targets--what are the challenges? Nat. Rev. Drug Discov., 2013, 12(4), 265-286.
[23]
Mirza, A.; Basso, A.; Black, S.; Malkowski, M.; Kwee, L.; Patcher, J.A.; Lachowicz, J.E.; Wang, Y.; Liu, S. RNA interference targeting of a1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol. Ther., 2005, 4(12), 1355-1360.
[24]
Zhou, Y.; Tong, L.; Chu, X.; Deng, F.; Tang, J.; Tang, Y.; Dai, Y. The adenosine a1 receptor antagonist dpcpx inhibits tumor progression via the erk/jnk pathway in renal cell carcinoma. Cell. Physiol. Biochem., 2017, 43(2), 733-742.
[25]
Jin, D.; Fan, J.; Wang, L.; Thompson, L.F.; Liu, A.; Daniel, B.J.; Shin, T.; Curiel, T.J.; Zhang, B. CD73 on tumor cells impairs antitumor t-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res., 2010, 70(6), 2245-2255.
[26]
Corbelini, P.F.; Figueiró, F. das Neves, G.M.; Andrade, S.; Kawano, D.F.; Oliveira Battastini, A.M.; Eifler-Lima, V.L. Insights into Ecto-5′-nucleotidase as a new target for cancer therapy: A medicinal chemistry study. Curr. Med. Chem., 2015, 22(15), 1776-1792.
[27]
Barcz, E.; Sommer, E.; Janik, P.; Marianowski, L.; Skopinska-Rózewska, E. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol. Rep., 2000, 7(6), 1285-1291.
[28]
Repetto, G.; Peso, A.; del Zurita, J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc., 2008, 3(7), 1125-1131.
[29]
Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 1984, 22, 27-55.
[30]
Klapperstück, T.; Glanz, D.; Klapperstück, M.; Wohlrab, J. Methodological aspects of measuring absolute values of membrane potential in human cells by flow cytometry. Cytometry A, 2009, 75A(7), 593-608.
[31]
Perry, S.W.; Norman, J.P.; Barbieri, J.; Brown, E.B.; Gelbard, H.A. Mitochondrial membrane potential probes and the proton gradient: A practical usage guide. Biotechniques, 2011, 50(2), 98-115.
[32]
Leone, R.D.; Emens, L.A. Targeting adenosine for cancer immunotherapy. J. Immunother. Cancer, 2018, 6(1), 57.
[33]
Soleimani, A.; Bahreyni, A.; Roshan, M.K.; Soltani, A.; Ryzhikov, M.; Shafiee, M.; Soukhtanloo, M.; Jaafari, M.R.; Mashkani, B.; Hassanian, S.M. Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives. J. Cell. Physiol., 2019, 234(3), 2329-2336.
[34]
Schiedel, A.C.; Lacher, S.K.; Linnemann, C.; Knolle, P.A.; Müller, C.E. Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms. Purinergic Signal., 2013, 9(3), 351-365.
[35]
Sun, W.; Moore, J.N.; Hurley, D.J.; Vandenplas, M.L.; Murray, T.F. Effects of stimulation of adenosine A2A receptors on lipopolysaccharide-induced production of reactive oxygen species by equine neutrophils. Am. J. Vet. Res., 2007, 68(6), 649-656.
[36]
Sun, W-C.; Moore, J.N.; Hurley, D.J.; Vandenplas, M.L.; Linden, J.; Cao, Z.; Murray, T.F. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes. Vet. Immunol. Immunopathol., 2008, 121(1-2), 91-100.
[37]
Kilian, J.G.; Nakhla, S.; Sieveking, D.P.; Celermajer, D.S. Adenosine prevents neutrophil adhesion to human endothelial cells after hypoxia/reoxygenation. Int. J. Cardiol., 2005, 105(3), 322-326.
[38]
Mueller, S.; Schittenhelm, M.; Honecker, F.; Malenke, E.; Lauber, K.; Wesselborg, S.; Hartmann, J.T.; Bokemeyer, C.; Mayer, F. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int. J. Oncol., 2006, 29(2), 471-479.
[39]
Daly, J.W. Caffeine analogs: Biomedical impact. Cell. Mol. Life Sci., 2007, 64(16), 2153-2169.
[40]
Chen, Y.; Hao, L-J.; Hung, C.; Chen, J.; Leu, S.; Huang, B. Apoptotic effect of cisplatin and cordycepin on oc3 human oral cancer cells. Chin. J. Integr. Med., 2013, 20(8), 624-632.
[41]
Gill, A.; Wortham, K.; Costa, D.; Davis, W.; Ticho, B.; Whalley, E. Protective effect of tonapofylline(BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am. J. Nephrol., 2009, 30(6), 521-526.
[42]
Tortora, G.; di Isernia, G.; Sandomenico, C.; Bianco, R.; Pomatico, G.; Pepe, S.; Bianco, A.R.; Ciardiello, F. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-CAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res., 1997, 57(22), 5107-5111.
[43]
Salamone, J.D. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. Drugs Investig. Drugs J., 2010, 13(10), 723-731.
[44]
Hirama, M.; Isonishi, S.; Yasuda, M.; Ishikawa, H. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol. Rep., 2006, 16(5), 997-1002.
[45]
Pathak, R.K.; Wen, R.; Kolishetti, N.; Dhar, S. A prodrug of two approved drugs, cisplatin and chlorambucil, for chemo war against cancer. Mol. Cancer Ther., 2017, 16(4), 625-636.
[46]
Knight, R.J.; Collis, M.G.; Yates, M.S.; Bowmer, C.J. Amelioration of cisplatin-induced acute renal failure with 8-cyclopentyl-1,3-dipropylxanthine. Br. J. Pharmacol., 1991, 104(4), 1062-1068.
41
7